Analysis of glucagon-like peptide 1; what to measure?
Authors:
- Annemieke C. HeijboerAHAnnemieke C. Heijboer
- Anneke FransAFAnneke Frans
- Marie LomeckyMLMarie Lomecky
- Marinus A. BlankensteinMBMarinus A. Blankenstein
- 1 June 2011
- journal article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 412 (13-14) , 1191-1194
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The spectrum of antidiabetic actions of GLP-1 in patients with diabetesBest Practice & Research Clinical Endocrinology & Metabolism, 2009
- GLP-1: Broadening the incretin concept to involve gut motilityRegulatory Peptides, 2009
- GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effectsCurrent Atherosclerosis Reports, 2009
- Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005Diabetologia, 2006
- Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control SubjectsDiabetes, 2004
- Similar Elimination Rates of Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients and Healthy SubjectsThe Journal of Clinical Endocrinology & Metabolism, 2003
- Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptidesRegulatory Peptides, 1999
- Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine IntestineEndocrinology, 1999
- Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivoThe Journal of Clinical Endocrinology & Metabolism, 1995
- Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishableDiabetes, 1993